ASCO GU 2022 VL

Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore

Details
Joining Alicia Morgans is Neal Shore to further highlight his team's presentation at this year's GU ASCO 2022 Annual Meeting focusing on evaluating the feasibility of instituting a hereditary cancer risk assessment (HCRA) protocol in their urological practice for prostate cancer patients. The results found were encouraging for the incorporation of recommended genomic screenings in community urolog...

Highlights of Urothelial and Prostate Cancer - 2022 GU ASCO Meeting - Scott Tagawa

Details
Joining Alicia Morgans is Scott Tagawa to review this year's GU ASCO 2022 highlights in prostate cancer and urothelial cancer. Dr. Tagawa highlights multiple presentations including the phase 1/2 study of ARV-110, The Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES), the VISION Phase 3 Trial, TROPHY-U-01 Cohort...

The Impact of Imaging and Therapeutics Advances in Nonmetastatic Castration-Resistant Prostate Cancer - David Penson

Details
David Penson joins Alicia Morgans to discuss the rapidly changing landscape in prostate cancer, focusing on how imaging and therapeutic advances have disrupted the landscape in the nonmetastatic castration-resistant prostate cancer (CRPC) setting. Dr. Penson highlights advancements in PSMA scanning and how it impacts potential study inclusion criteria. Drs. Morgans and Penson also discuss PSMA PET...

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip

Details
Wesley Yip and Sam Chang discuss the results of a multicenter trial of neoadjuvant gemcitabine and cisplatin in patients with upper tract urothelial carcinoma (UTUC) presented at the ASCO GU 2022 Cancer Symposium. This phase II multicenter trial of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-risk UTUC prior to extirpative surgery sought to evaluate major outcomes...

Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye

Details
Sam Chang is joined by Deborah Kaye to discuss the "best papers" in urothelial carcinoma that she highlighted for her presentation at the GU ASCO 2022 Annual Meeting. She highlights four papers on urothelial carcinoma that she selected based on their clinical relevance and how they have a direct impact on bladder cancer patients today. Biographies: Deborah Kaye, MD, MS, Urologic Oncologist, Assist...

Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...

Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez

Details
Alicia Morgans is joined by Brian Gonzalez to discuss work he presented at GU ASCO 2022 on patient-reported quality of life metrics among men receiving prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study being discussed treated 50 patients, between 2015 to 2017, with up to 4 cycles of 177Lu-PSM...

Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian

Details
At the 2022 ASCO GU meeting, Stephen Boorjian chaired a rapid abstract session in urothelial carcinoma focusing on three broad topics in advanced urothelial cancer. One abstract covers the role of neoadjuvant chemotherapy with gemcitabine and cisplatin, for patients with upper tract urothelial carcinoma. One abstract covers maintenance therapy with a checkpoint inhibitor, for patients who've not e...

A Real-World Study of PSA Response in Black and White Chemotherapy-Naive Prostate Cancer Patients Treated With Enzalutamide - Alicia Morgans

Details
Oliver Sartor and Alicia Morgans discuss her recent presentation at GU ASCO 2022 on the results of a study assessing PSA outcomes in black and white chemotherapy-naïve prostate cancer patients treated with enzalutamide. This study assessed real-world PSA outcomes (response and progression) of enzalutamide-treated black vs white patients with prostate cancer patients in the US. Dr. Morgans and coll...

Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore

Details
In this discussion, Neal Shore joins Alicia Morgans in a conversation about a clinical trial for patients with mHSPC, the ARASEC trial. This study is designed to demonstrate how well darolutamide administered together with androgen deprivation therapy works in men with metastatic hormone-sensitive prostate cancer. Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic...